Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Prostatic Neoplasms 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Etoposide 3prednylidene 2deltacortene 2Vincristine 2Rituximab 2Prednisone 2Doxorubicin 2Cytarabine 2Cyclophosphamide 2merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Hydrocortisone 1Carmustine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Plasmablastic Lymphoma × Hydrocortisone × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡